NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

NOVO.B.DK

300.1

+1.18%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

Home・Aktien・Coloplast A-S (Class B)

Coloplast A-S (Class B)

Geschlossen

400.3 -1.6

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

397.9

Max

400.4

Schlüsselkennzahlen
By Trading Economics
Einkommen	522M 1.4B
Verkäufe	83M 7B
KGV Branchendurchschnitt	22.633 51.415
EPS	6.32
Dividendenrendite	5.74
Gewinnspanne	19.835
Angestellte	16,983
EBITDA	309M 2.3B

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+11.86% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	5.74% 2.34%

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-28B 90B
Vorheriger Eröffnungskurs	401.9
Vorheriger Schlusskurs	400.3

Coloplast A-S (Class B) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Coloplast A-S (Class B) Prognose

Kursziel

By TipRanks

11.86% Vorteil

12-Monats-Prognose

Durchschnitt 901.38 DKK 11.86%

Hoch 1,056 DKK

Tief 720 DKK

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Coloplast A-S (Class B) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Coloplast A-S (Class B) – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.